[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.148.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1986

Pulmonary InfectionsThe Minnesota Randomized Prospective Trial of Cyclosporine vs Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients

Author Affiliations

From the Department of Surgery, University of Minnesota Hospitals, Minneapolis. Dr Hesse is now with the Department of Surgery, University of Cologne, Federal Republic of Germany.

Arch Surg. 1986;121(9):1056-1060. doi:10.1001/archsurg.1986.01400090086015
Abstract

• Nineteen of 224 renal allograft recipients who were prospectively randomized to receive either cyclosporine (n = 117) or azathioprine sodium—antilymphocyte globulin (n = 107) for immunosuppression suffered from one period of pneumonia (14 azathioprine and five cyclosporine recipients); two recipients of azathioprine had two episodes. Four patients in the azathioprine group and one in the cyclosporine group died, for mortalities of 3.7% and 0.85%, respectively. The percentage of pneumonia-free patients at one year was 96.3% in the cyclosporine group while it was 90.8% in the azathioprine group. Nondiabetics, women, and recipients of grafts from living related donors were at a statistically lower risk of developing pneumonia when treated with cyclosporine. Viral (cytomegalovirus), fungal (Candida, Aspergillus), and multibacterial causes of pneumonia each occurred with a similar incidence.

(Arch Surg 1986;121:1056-1060)

×